Cancer Biomarker Testing Market to Reach US$ 96.53 Billion by 2033, Growing at a CAGR of 12.6% | Key Players: Illumina, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, QIAGEN, Siemens Healthineers AG

Market Overview:

The global cancer biomarker testing market was valued at US$ 29.83 Billion in 2023. The market reached US$ 33.37 Billion in 2024 and is expected to grow to US$ 96.53 Billion by 2033, registering a CAGR of 12.6% during the forecast period 2025-2033. The market growth is primarily driven by the rising prevalence of cancer worldwide, emphasizing the need for early diagnosis and personalized therapies. Technological advancements in diagnostic platforms such as next-generation sequencing (NGS), liquid biopsy, AI-powered analytics, and multiplex biomarker panels are making testing more precise, faster, and cost-effective.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/cancer-biomarker-testing-market?Juli

A significant trend in the market is the shift toward personalized medicine, where biomarker testing guides treatment selection based on an individual patient's molecular profile. Liquid biopsy technologies are increasingly adopted due to their non-invasive nature, enabling real-time disease monitoring and early detection of recurrence. Integration of multi-omics data including genomics, proteomics, and metabolomics is enhancing diagnostic precision and therapeutic stratification.

Recent Key Developments:

✅ January 2026 (Product Launch): Roche Diagnostics launched an advanced multi-cancer liquid biopsy panel capable of detecting early-stage mutations across multiple tumor types, enabling personalized therapy selection and real-time disease monitoring.

✅ December 2025 (Partnership): Thermo Fisher Scientific partnered with a leading biopharmaceutical company to integrate next-generation sequencing (NGS) biomarker testing with clinical trial workflows, accelerating patient stratification and precision oncology initiatives.

✅ November 2025 (Platform Upgrade): Qiagen released an updated version of its digital PCR platform for cancer biomarker detection, offering higher sensitivity, faster turnaround times, and compatibility with both tissue and liquid biopsy samples.

✅ October 2025 (Acquisition): Guardant Health acquired a precision oncology startup specializing in non-invasive genomic profiling to expand its liquid biopsy product portfolio and strengthen capabilities in rare cancer detection.

Recent Key Developments: North America / Asia Pacific
✅ January 2026 (Implementation): A leading U.S. hospital network implemented AI-powered cancer biomarker testing across its oncology departments, enabling rapid mutation detection for lung, breast, and colorectal cancers.

✅ December 2025 (Launch): A major Asian diagnostics firm introduced a multi-cancer liquid biopsy test in China and India, aimed at early detection and therapy guidance in high-risk populations.

✅ November 2025 (Contract Win): A U.S.-based biomarker testing company secured a multi-year agreement with a governmental healthcare agency to provide nationwide biomarker screening for cancer research and prevention programs.

✅ October 2025 (Collaboration): An Indian biotech company collaborated with an international AI analytics provider to implement real-time biomarker data interpretation for personalized treatment recommendations in oncology clinics.

✅ In May 2025, Cizzle Bio, Inc., a biotechnology company specializing in innovative cancer diagnostics, agreed with Doctors Hospital in the Cayman Islands to provide its advanced blood-based tests for early cancer detection. Specifically, the hospital's clinical laboratory will now offer Cizzle Bio's CIZ1B lung cancer test and DEX-G2 gastric cancer test.

✅ In February 2025, Imagene, a company specializing in artificial intelligence (AI) solutions for oncology, announced a collaboration with Tempus AI, Inc., a technology leader in AI-driven precision medicine. The goal of this partnership is to advance cancer diagnostics by leveraging the strengths of both companies in AI and clinical data.

Key Players:
Illumina, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, QIAGEN, Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Agilent Technologies, BioMérieux, and Foundation Medicine, Inc.

Illumina, Inc. - Specializing in next-generation sequencing (NGS) and genomic solutions.

F. Hoffmann-La Roche Ltd - Offers advanced diagnostics, liquid biopsy, and oncology biomarker platforms.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=cancer-biomarker-testing-market?Juli

Market Dynamics:
Drivers
Emergence of Multi-Omics and AI-Driven Diagnostics
The rise of multi-omics and AI-driven diagnostics is a significant driver for the global cancer biomarker testing market. Multi-omics integrates genomics, transcriptomics, proteomics, and metabolomics to provide a holistic view of cancer biology, improving early detection and enabling the discovery of novel biomarkers.

In May 2025, BioMark Diagnostics Inc. published a study on AI-driven lung cancer detection using metabolomics and graph neural networks, demonstrating superior predictive performance.

In April 2025, 1Cell.Ai launched OncoIncytes, a multi-omics platform integrating genomics, transcriptomics, proteomics, and metabolomics for precise cancer profiling.

In August 2024, io9 introduced the DeepHRD model, an AI-powered biomarker test outperforming traditional next-generation sequencing (NGS) and FDA-approved homologous recombination deficiency (HRD) diagnostics.

Restraints:
High Cost of Biomarker Tests and Drug Development
The cost of advanced biomarker tests and associated drug development is a major restraint. Cutting-edge technologies, including NGS, multiplex assays, and specialized lab equipment, require significant investment and skilled personnel.

High infrastructure and operational costs make tests expensive and limit accessibility, particularly in low- and middle-income countries.

Pharmaceutical and diagnostic companies incur substantial expenses in discovery, validation, regulatory approval, and market launch, often passing these costs to healthcare providers and patients.

Limited affordability can slow widespread adoption, despite the clinical benefits of early and precise cancer detection.

Opportunities:
Development of Novel Biomarkers
The discovery and implementation of novel biomarkers present a key opportunity to advance early detection, improve treatment precision, and enable personalized cancer management.

Emerging biomarkers such as tumor mutation burden (TMB), microsatellite instability (MSI), and tumor-infiltrating lymphocytes (TILs) are being studied to refine diagnostics and guide therapy selection.

In April 2025, Artera partnered with Tempus to expand access to the ArteraAI Prostate Test, leveraging multimodal AI to stratify prostate cancer risk and guide personalized treatment.

Novel biomarkers help clinicians identify patients most likely to benefit from specific therapies, optimizing treatment efficacy and minimizing unnecessary interventions.

Regional Insights:

North America: 40.5% (Largest share) - Growth is driven by advanced healthcare infrastructure, high adoption of AI and multi-omics diagnostics, strong presence of key market players, and high R&D investment in precision medicine and cancer research in the U.S. and Canada.

Asia Pacific: 25% (Fastest-growing) - Expansion is fueled by rapid digitalization, increasing awareness of early cancer detection, improving healthcare infrastructure, and adoption of AI-powered and cloud-based diagnostic solutions in countries like China, India, and Japan.

Europe: 20% - Growth is supported by stringent regulatory compliance, government-backed digital health initiatives, rising investments in personalized medicine, and automation in laboratory and clinical diagnostics across Germany, the U.K., and France.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/cancer-biomarker-testing-market?Juli

Market Segmentation:

By Test Type
Genetic Biomarker Testing: 32% - Widely adopted for early detection and precision medicine, leveraging NGS and PCR technologies.

Protein Biomarker Testing: 20% - Used for prognosis and monitoring therapeutic responses in cancers such as breast and prostate.

Circulating Tumor DNA (ctDNA) Testing: 18% - Growing demand due to its non-invasive nature and use in liquid biopsy applications.

Polymerase Chain Reaction (PCR): 15% - Highly used in clinical labs for targeted gene analysis and mutation detection.

Next-Generation Sequencing (NGS): 15% - Key driver for multi-omics and comprehensive cancer profiling.

By Product Type
Instruments: 45% - Includes PCR machines, NGS platforms, mass spectrometers, and ctDNA detection devices; essential for high-throughput testing and advanced diagnostics.

Kits & Reagents: 55% - High consumption due to frequent replacement, usage across multiple tests, and increasing adoption in laboratories and hospitals.

By Cancer Type
Lung Cancer: 25% - Large share due to high incidence and focus on early detection and personalized therapy.

Prostate Cancer: 18% - Rising prevalence and demand for targeted screening tests drive adoption.

Breast Cancer: 20% - Widespread biomarker testing for early detection, recurrence monitoring, and therapy guidance.

Leukemia: 15% - Growth supported by molecular diagnostics and monitoring of minimal residual disease.

Other Cancers: 22% - Includes ovarian, colorectal, pancreatic, and rare cancers, where biomarker-driven diagnostics are expanding.

By Application
Drug Discovery and Development: 28% - Biomarker testing aids in identifying therapeutic targets and patient stratification for clinical trials.

Disease Screening: 30% - Early detection of cancers is a major driver of market adoption globally.

Treatment Planning: 25% - Enables personalized therapy selection, dosing, and monitoring of response.

Others: 17% - Includes prognosis assessment, monitoring recurrence, and research purposes.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli give title

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.